Oncotarget

Research Papers:

KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies

Wei Pan, Yan Yang, Hongcheng Zhu, Youcheng Zhang, Rongping Zhou and Xinchen Sun _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:8373-8388. https://doi.org/10.18632/oncotarget.7080

Metrics: PDF 1519 views  |   HTML 1557 views  |   ?  


Abstract

Wei Pan1,2, Yan Yang1, Hongcheng Zhu1, Youcheng Zhang3, Rongping Zhou3, Xinchen Sun1

1Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P.R. China

2Department of Oncology, The Second Hospital of Nanjing Jiangning, Nanjing, Jiangsu, P.R. China

3Department of Oncology, Nanjing Jiangning Hospital, Nanjing, Jiangsu, P.R. China

Correspondence to:

Xinchen Sun, e-mail: starrystyle@hotmail.com

Keywords: non-small cell lung cancer, KRAS mutation, prognosis, EGFR-TKI, meta-analysis

Received: July 30, 2015     Accepted: January 13, 2016     Published: January 30, 2016

ABSTRACT

Mutation of oncogene KRAS is common in non-small cell lung cancer (NSCLC), however, its clinical significance is still controversial. Independent studies evaluating its prognostic and predictive value usually drew inconsistent conclusions. Hence, We performed a meta-analysis with 41 relative publications, retrieved from multi-databases, to reconcile these controversial results and to give an overall impression of KRAS mutation in NSCLC. According to our findings, KRAS mutation was significantly associated with worse overall survival (OS) and disease-free survival (DFS) in early stage resected NSCLC (hazard ratio or HR=1.56 and 1.57, 95% CI 1.39-1.76 and 1.17-2.09 respectively), and with inferior outcomes of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) treatment and chemotherapy (relative risk or RR=0.21 and 0.66 for objective response rate or ORR, 95% CI 0.12-0.39 and 0.54-0.81 respectively; HR=1.46 and 1.30 for progression-free survival or PFS, 95%CI 1.23-1.74 and 1.14-1.50 respectively) in advanced NSCLC. When EGFR mutant patients were excluded, KRAS mutation was still significantly associated with worse OS and PFS of EGFR-TKIs (HR=1.40 and 1.35, 95 % CI 1.21-1.61 and 1.11-1.64). Although KRAS mutant patients presented worse DFS and PFS of chemotherapy (HR=1.33 and 1.11, 95% CI 0.97-1.84 and 0.95-1.30), and lower response rate to EGFR-TKIs or chemotherapy (RR=0.55 and 0.88, 95 % CI 0.27-1.11 and 0.76-1.02), statistical differences were not met. In conclusion, KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC. There’s a need for developing target therapies for KRAS mutant lung cancer and other tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7080